Indiana Senate Bill 282 established new requirements for drug compounding oversight and mandates that Med Spas register with the Indiana Medical Licensing Board starting January 1, 2027. The law also requires facilities to designate practitioners accountable for oversight, adverse-event reporting, and advertising compliance, which introduces new regulatory obligations for Indiana Med Spa operators.
Indiana Enacts SB 282 Establishing Med Spa Registration Requirements
On March 5, 2026, Indiana Governor Mike Braun signed Senate Bill 282 into law, establishing new state oversight requirements for drug compounding and Med Spa operations. Authored by Sen. Ed Charbonneau and Sen. Justin Busch, the legislation requires Med Spas operating in Indiana to register with the state’s Medical Licensing Board beginning January 1, 2027. The new law applies to facilities that offer cosmetic or lifestyle treatments involving prescription medications and introduces state reporting and operational obligations for registered Med Spas.
Current Law and 2027 Registration Requirements Under Indiana SB 282
Before SB 282, Indiana statutes did not establish a specific regulatory category for Med Spas. Procedures such as cosmetic injections or IV therapies that involve prescription drugs fall under the practice of medicine, which is regulated by the Indiana Medical Licensing Board pursuant to the Indiana Medical Practice Act (IC 25-22.5). Under Indiana Senate Bill 282, Med Spas will be required to register with the Indiana Medical Licensing Board, which will maintain a public registry of facilities and oversee compliance through designated responsible practitioners.
SB 282 establishes a new statutory framework, which became Public Law on March 5, 2026, and takes effect in stages. The new Med Spa regulatory chapter will become part of the Indiana Code on July 1, 2026, and the Indiana Medical Licensing Board must establish the registration process by October 1, 2026. However, the bill’s registration mandate does not take effect until January 1, 2027.
The key Med Spa operational requirements established by the SB 282 will include:
- Registering the Med Spa with the Indiana Medical Licensing Board by January 1, 2027.
- Designating a licensed “responsible practitioner” who is accountable for medical oversight in the facility.
- Reporting adverse effects associated with administered treatments to the Medical Licensing Board.
- Disclosures during Med Spa registration of facility ownership, offered services, and whether prescription drugs are compounded on-site.
- Complying with state health care advertising rules governing cosmetic and lifestyle treatments.
- Med Spa services may only be provided at the registered facility location, rather than in mobile or off-site settings.
Additionally, the bill states that operators who provide Med Spa services without registering after the requirement takes effect may face civil penalties and disciplinary review by the responsible practitioner’s licensing board.
Legislative Source: Indiana Senate Bill 282
According to Indiana Senate Bill 282, signed into law by Indiana Governor Mike Braun on March 5, 2026, the new legislation establishes oversight provisions for drug compounding. It requires Med Spas to register with the Indiana Medical Licensing Board beginning January 1, 2027.
Oversight of Medical Spas and Compounded Drugs Expands Under SB 282
Under Indiana Senate Bill 282, the Indiana Medical Licensing Board will oversee the state’s Med Spa registrations beginning January 1, 2027. This oversight includes maintaining a public database of registered facilities and reviewing complaints involving any designated responsible practitioners.
Drug compounding and the use of prescription medications in Med Spa settings have drawn regulatory attention to advertising and treatment oversight practices. According to SB 282, the law will also require the Indiana Board of Pharmacy, the Indiana Medical Licensing Board, and the Indiana State Department of Health to prepare a report for the Indiana General Assembly evaluating the risks and benefits of drug compounding.
In similar oversight news, in Texas, lawmakers debated legislation that initially proposed stricter physician supervision requirements for Med Spa procedures. This ultimately led to House Bill 3749, which focuses on regulating elective IV therapy provided outside traditional healthcare facilities. At the federal level, the FDA announced on March 3, 2026, that it issued warning letters to telehealth companies advertising compounded versions of GLP-1 drugs, citing misleading direct-to-consumer advertising.
Med Spa operators who facilitate compounded formulations administered by injection or IV therapy may face increasing oversight from the Indiana Medical Board, pharmacy regulators, and federal drug authorities as new regulations and oversight systems are established.
Operational Considerations for Indiana Medical Spa Operators
- Confirm whether your clinic meets SB 282’s definition of a Med Spa:
Under SB 282, a facility qualifies if it:
- Provides health care services.
- Uses prescription drugs administered intravenously, intramuscularly, or subcutaneously.
- Promotes or markets cosmetic or lifestyle treatments.
- Prepare for the 2027 registration requirement: Gather facility details, including ownership information, services offered, and practitioner oversight arrangements.
- Designate a responsible practitioner who will oversee clinical services, ensure regulatory compliance, and serve as the primary contact with the Medical Licensing Board.
- Implement a process to document and report serious adverse events to the Indiana Medical Licensing Board, as required under SB 282.
- Evaluate sourcing and handling for compounded medications: Ensure pharmacies and prescribing practices comply with Indiana pharmacy law and federal compounding standards.
Next Steps and Implementation Timeline Under SB 282
Following its enactment on March 5, 2026, Indiana Senate Bill 282 directs the Indiana Medical Licensing Board to establish a Med Spa registration program. The law also requires the Indiana Board of Pharmacy, the Indiana Medical Licensing Board, and the Indiana Department of Health to prepare a report for the General Assembly evaluating the risks and benefits of drug compounding. Med Spa operators must comply with the state registration requirement beginning January 1, 2027.
About Spakinect
Spakinect provides compliance infrastructure and telehealth-supported supervision solutions for medical aesthetic practices. For additional information, see our main page.
“Indiana State Capitol” by Massimo Catarinella, via Wikimedia Commons, licensed under CC BY-SA 2.5.
